

# A novel signaling pathway involved in thromboxane A<sub>2</sub> receptor-mediated vascular contraction

Kimiaki SUZUKI

*Department of Pharmacology, Graduate School of Pharmaceutical Sciences*

Thromboxane A<sub>2</sub> (TXA<sub>2</sub>) is one of the eicosanoids produced by the arachidonate cascade, and its biological activity is mediated by G protein-coupled TXA<sub>2</sub> receptors, i.e., TP receptors. Although TXA<sub>2</sub> is well known as a potent vasoconstrictor, the detailed understanding of the signaling pathways involved in TP receptor-mediated contraction remains to be fully elucidated. We have previously shown that low concentrations ( $\leq 30$  nM) of U46619, a stable TXA<sub>2</sub> analog, induces extracellular Ca<sup>2+</sup>-dependent contraction mediated via voltage-dependent Ca<sup>2+</sup> channels (VDCC) and cation channels in rat aorta. In the present study, we focused on lipid signaling, which may be involved in the Ca<sup>2+</sup> influx induced by U46619.

U46619 (20 nM) induced contraction and [Ca<sup>2+</sup>]<sub>i</sub> elevation in the ring preparations of isolated rat aorta. These effects were not inhibited by U73122, an inhibitor of phosphatidylinositol-specific phospholipase C (PI-PLC) that produces inositoltriphosphate (IP<sub>3</sub>) and diacylglycerol (DAG) from phosphatidylinositol. The  $\alpha_1$  adrenergic agonist phenylephrine, which activates PI-PLC, elicited a transient increase in [Ca<sup>2+</sup>]<sub>i</sub>, possibly mediated by IP<sub>3</sub>, in Ca<sup>2+</sup>-free extracellular solution, whereas U46619 had no effect on [Ca<sup>2+</sup>]<sub>i</sub>. These results suggest that Ca<sup>2+</sup> release from sarcoplasmic reticulum (SR) is involved in the [Ca<sup>2+</sup>]<sub>i</sub> elevation mediated by  $\alpha_1$ -adrenoceptors, but not by TP receptors. In contrast, the U46619-induced contraction and [Ca<sup>2+</sup>]<sub>i</sub> elevation were abolished by D609, a phosphatidylcholine-specific phospholipase C (PC-PLC) that produces DAG from phosphatidylcholine. Although the involvement of DAG was suggested, the effects of U46619 were not inhibited by GF109203X, a protein kinase C (PKC) inhibitor.

Taken together with these results, we propose the following mechanism: U46619 stimulates PC-PLC, which increases DAG production. The produced DAG opens cation channels independently of the activation of PKC, which leads to VDCC activation via depolarization. Then, extracellular Ca<sup>2+</sup> influx via VDCC and cation channels increases [Ca<sup>2+</sup>]<sub>i</sub>, thereby eliciting vascular contraction.